Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2017 (2017), Article ID 9320802, 5 pages
https://doi.org/10.1155/2017/9320802
Research Article

Serum Glutamate Is a Predictor for the Diagnosis of Multiple Sclerosis

1Department of Neurology, Baghdad Teaching Hospital, Medical City, College of Medicine, University of Baghdad, Baghdad, Iraq
2Department of Microbiology & Immunology, College of Medicine, University of Baghdad, Baghdad, Iraq

Correspondence should be addressed to Inas K. Sharquie; moc.oohay@eiuqrahski

Received 6 March 2017; Revised 3 May 2017; Accepted 9 May 2017; Published 6 June 2017

Academic Editor: Maria Grazia Grasso

Copyright © 2017 Gheyath Al Gawwam and Inas K. Sharquie. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Brück and C. Stadelmann, “The spectrum of multiple sclerosis: new lessons from pathology,” Current Opinion in Neurology, vol. 18, no. 3, pp. 221–224, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. F. D. Lublin, S. C. Reingold, J. A. Cohen et al., “Defining the clinical course of multiple sclerosis: the 2013 revisions,” Neurology, vol. 83, no. 3, pp. 278–286, 2014. View at Google Scholar
  3. J. Newcombe, A. Uddin, R. Dove et al., “Glutamate receptor expression in multiple sclerosis lesions,” Brain Pathology, vol. 18, no. 1, pp. 52–61, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. I. R. Stojanovic, M. Kostic, and S. Ljubisavljevic, “The role of glutamate and its receptors in multiple sclerosis,” Journal of Neural Transmission, vol. 121, no. 8, pp. 945–955, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. R. P. Bunge, “Glial cells and the central myelin sheath,” Physiological Reviews, vol. 48, no. 1, pp. 197–251, 1968. View at Google Scholar
  6. A. Compston and A. Coles, “Multiple sclerosis,” The Lancet, vol. 372, no. 9648, pp. 1502–1517, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. D. S. P. Schubert and R. H. Foliart, “Increased depression in multiple sclerosis patients: a meta-analysis,” Psychosomatics, vol. 34, no. 2, pp. 124–130, 1993. View at Publisher · View at Google Scholar · View at Scopus
  8. B. S. Meldrum, “Glutamate as a neurotransmitter in the brain: review of physiology and pathology,” Journal of Nutrition, vol. 130, supplement 4, pp. 1007S–1015S, 2000. View at Google Scholar
  9. J. E. Adams, H. A. Harper, G. S. Gordan, M. Hutchin, and R. C. Bentinck, “Cerebral metabolism of glutamic acid in multiple sclerosis,” Neurology, vol. 5, no. 2, pp. 101–107, 1955. View at Publisher · View at Google Scholar · View at Scopus
  10. J. J. G. Geurts, G. Wolswijk, L. Bö et al., “Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis,” Brain, vol. 126, part 8, pp. 1755–1766, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. E. MacMillan, R. Tam, Y. Zhao et al., “Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years,” Multiple Sclerosis Journal, vol. 22, no. 1, pp. 112–116, 2016. View at Publisher · View at Google Scholar
  12. P. Werner, D. Pitt, and C. S. Raine, “Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyre and axonal damage,” Annals of Neurology, vol. 50, no. 2, pp. 169–180, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Park, A. A. Velumian, and M. G. Fehlings, “The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration,” Journal of Neurotrauma, vol. 21, no. 6, pp. 754–774, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. R. A. Hawkins, “The blood-brain barrier and glutamate,” The American Journal of Clinical Nutrition, vol. 90, no. 3, pp. 867S–874S, 2009. View at Publisher · View at Google Scholar
  15. A. Minagar and J. S. Alexander, “Blood-brain barrier disruption in multiple sclerosis,” Multiple Sclerosis, vol. 9, no. 6, pp. 540–549, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Compston and A. Coles, “Multiple sclerosis,” The Lancet, vol. 359, no. 9313, pp. 1221–1231, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. D. H. Miller, B. G. Weinshenker, M. Filippi et al., “Differential diagnosis of suspected multiple sclerosis: a consensus approach,” Multiple Sclerosis, vol. 14, no. 9, pp. 1157–1174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. C. M. Poser, D. W. Paty, L. Scheinberg et al., “New diagnostic criteria for multiple sclerosis: guidelines for research protocols,” Annals of Neurology, vol. 13, no. 3, pp. 227–231, 1983. View at Publisher · View at Google Scholar · View at Scopus
  19. A. S. Rose, G. W. Ellison, L. W. Myers, and W. W. Tourtellotte, “Criteria for the clinical diagnosis of multiple sclerosis,” Neurology, vol. 26, no. 6, part 2, pp. 20–22, 1976. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Bove, A. Musallam, B. C. Healy et al., “No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50,” BMC Neurology, vol. 13, article 73, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. S.-M. Orton, B. M. Herrera, I. M. Yee et al., “Sex ratio of multiple sclerosis in Canada: a longitudinal study,” The Lancet Neurology, vol. 5, no. 11, pp. 932–936, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Toledano, B. G. Weinshenker, and A. J. Solomon, “A clinical approach to the differential diagnosis of multiple sclerosis,” Current Neurology and Neuroscience Reports, vol. 15, no. 8, article 57, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. J. F. Stover, U. E. Pleines, M. C. Morganti-Kossmann, T. Kossmann, K. Lowitzsch, and O. S. Kempski, “Neurotransmitters in cerebrospinal fluid reflect pathological activity,” European Journal of Clinical Investigation, vol. 27, no. 12, pp. 1038–1043, 1997. View at Publisher · View at Google Scholar
  24. P. Sarchielli, L. Greco, A. Floridi, A. Floridi, and V. Gallai, “Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid,” Archives of Neurology, vol. 60, no. 8, pp. 1082–1088, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Hardin-Pouzet, M. Krakowski, L. Bourbonniere, M. Didier-Bazes, E. Tran, and T. Owens, “Glutamate metabolism is down-regulated in astrocytes during experimental allergic encephalomyelitis,” Glia, vol. 20, no. 1, pp. 79–85, 1997. View at Publisher · View at Google Scholar
  26. F. C. Westall, A. Hawkins, G. W. Ellison, and L. W. Myers, “Abnormal glutamic acid metabolism in multiple sclerosis,” Journal of the Neurological Sciences, vol. 47, no. 3, pp. 353–364, 1980. View at Publisher · View at Google Scholar · View at Scopus